CRIF counteracts oncogenic Ras and regulates heterochromatin.

Area of Science:

• Cell Biology
• Genetics
• Cancer Research

Background:

• Oncogenic Ras mutations drive human cancers, but tumorigenesis mechanisms are unclear.
• Ras promotes tissue overgrowth and metastasis in Drosophila, but cellular restraints are unknown.

Purpose of the Study:

• Identify novel modifiers of oncogenic Ras (Ras^V12) in Drosophila.
• Investigate the role of Drosophila CRIF in Ras^V12-induced phenotypes and heterochromatin formation.

Main Methods:

• Genetic screens in Drosophila to identify modifiers of Ras^V12.
• Analysis of Ras^V12-induced lethality, overgrowth, and cell proliferation.
• Assays for heterochromatin formation, including position-effect variegation (PEV), HP1 levels, and H3K9me3.
• Co-immunoprecipitation to assess protein interactions.

Main Results:

• Drosophila CRIF (CR6-interacting factor 1) modifies Ras^V12 phenotypes; CRIF knockdown exacerbates, while overexpression ameliorates them.
• CRIF is essential for heterochromatin formation, suppressing PEV and reducing HP1 and H3K9me3 levels.
• CRIF physically interacts with HP1, influencing its localization but not transcription or total levels.

Conclusions:

• CRIF acts as a tumor suppressor by inhibiting cell proliferation and maintaining heterochromatin stability.
• CRIF's interaction with HP1 reveals a novel link between heterochromatin regulation and tumor suppression in Ras-driven cancers.
• CRIF represents a potential therapeutic target for Ras-driven cancers, offering new insights into chromatin regulation and oncogenic signaling.